Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AminoZorb is a patented dietary supplement and nutraceutical developed by Dr. Jeff Golini at All American Pharmaceuticals. It is a branched-chain amino acid (BCAA) formulation featuring a 2:1:1 ratio of L-leucine, L-isoleucine, and L-valine. The product utilizes an advanced delivery system and enzymatically fermented amino acids to enhance absorption and support muscle recovery, growth, and overall athletic performance. Some formulations, such as AminoZorb Elite 21, include a comprehensive profile of essential, non-essential, and conditionally essential amino acids along with GlutaZorb (a stable form of glutamine). It is primarily marketed within the sports nutrition industry for athletes seeking improved supplementation efficiency and muscle support.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on AminoZorb.